CONTEXT: A 2-day consensus conference was held to examine scientific and ethical issues in the application of deep brain stimulation for treating mood and behavioral disorders, such as major depression, obsessive-compulsive disorder, and Tourette syndrome. OBJECTIVES: The primary objectives of the conference were to (1) establish consensus among participants about the design of future clinical trials of deep brain stimulation for disorders of mood, behavior, and thought and (2) develop standards for the protection of human subjects participating in such studies. RESULTS: Conference participants identified 16 key points for guiding research in this growing field. CONCLUSIONS: The adoption of the described guidelines would help to protect the safety and rights of research subjects who participate in clinical trials of deep brain stimulation for disorders of mood, behavior, and thought and have further potential to benefit other stakeholders in the research process, including clinical researchers and device manufactures. That said, the adoption of the guidelines will require broad and substantial commitment from many of these same stakeholders.
CONTEXT: A 2-day consensus conference was held to examine scientific and ethical issues in the application of deep brain stimulation for treating mood and behavioral disorders, such as major depression, obsessive-compulsive disorder, and Tourette syndrome. OBJECTIVES: The primary objectives of the conference were to (1) establish consensus among participants about the design of future clinical trials of deep brain stimulation for disorders of mood, behavior, and thought and (2) develop standards for the protection of human subjects participating in such studies. RESULTS: Conference participants identified 16 key points for guiding research in this growing field. CONCLUSIONS: The adoption of the described guidelines would help to protect the safety and rights of research subjects who participate in clinical trials of deep brain stimulation for disorders of mood, behavior, and thought and have further potential to benefit other stakeholders in the research process, including clinical researchers and device manufactures. That said, the adoption of the guidelines will require broad and substantial commitment from many of these same stakeholders.
Authors: Bart Nuttin; Jan Gybels; Paul Cosyns; Loes Gabriels; Bjorn Meyerson; Sergej Andreewitch; Steven A Rasmussen; Benjamin Greenberg; Gerhard Friehs; Ali R Rezai; Erwin Montgomery; Don Malone; Joseph J Fins Journal: Neurosurg Clin N Am Date: 2003-04 Impact factor: 2.509
Authors: Benjamin D Greenberg; Lawrence H Price; Scott L Rauch; Gerhard Friehs; Georg Noren; Donald Malone; Linda L Carpenter; Ali R Rezai; Steven A Rasmussen Journal: Neurosurg Clin N Am Date: 2003-04 Impact factor: 2.509
Authors: Paul Greenberg; Patricia K Corey-Lisle; Howard Birnbaum; Maryna Marynchenko; Ami Claxton Journal: Pharmacoeconomics Date: 2004 Impact factor: 4.981
Authors: Maria I Lapid; Teresa A Rummans; Kristine L Poole; V Shane Pankratz; Megan S Maurer; Keith G Rasmussen; Kemuel L Philbrick; Paul S Appelbaum Journal: J ECT Date: 2003-06 Impact factor: 3.635
Authors: Michael R Gionfriddo; Alexandra J Greenberg; Abhijeet L Wahegaonkar; Kendall H Lee Journal: Clin Transl Sci Date: 2013-04-19 Impact factor: 4.689
Authors: Yan Leykin; Paul P Christopher; Paul E Holtzheimer; Paul S Appelbaum; Helen S Mayberg; Sarah H Lisanby; Laura B Dunn Journal: AJOB Prim Res Date: 2011-10